Mohammad O. Ramadan, MD, presented “Genetic Testing in Prostate Cancer” during the 5th Annual Oklahoma Prostate & Urologic Cancers Symposium on September 13th, 2019 in Oklahoma City, Oklahoma.

How to cite: Ramadan, Mohammad O. “Genetic Testing in Prostate Cancer” September 13th, 2019. Accessed May 2024.

Genetic Testing in Prostate Cancer – Summary:

Mohammad O. Ramadan, MD, discusses the importance of genetic testing for prostate cancer screening, diagnosis, and treatment. He notes that there is currently a professional practice gap in this area, even as genetic testing becomes more widely available. Studies suggest that approximately 17% of prostate cancer patients are biomarker positive, and therefore may benefit more than other patients from treatments like PARP inhibitors. Research like this has led the NCCN to recommend germline genetic testing for all men with high-risk, very-high-risk, regional, or metastatic prostate cancer. With this guideline in place, urologists will have to quickly figure out how to provide widespread testing, and may have to partner with geneticists.

About The 5th Annual Prostate & Urologic Cancer Symposium:

The Prostate & Urologic Cancers Symposium is held through the University of Oklahoma and the Stephenson Cancer Center to provide new insights in the treatment of prostate and urologic cancers. This single-day program consists of lectures and case discussions highlighting a multidisciplinary approach to urologic cancer care and integration of new technology in the evaluation and treatment of patients with prostate and/or urologic cancers. Dr. Ramadan presented this lecture during the 5th iteration of this summit in 2019.

Please click here for further educational content from this conference.